Skip to main content
Powered by ShareScore

Find research datasets worth reusing

Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.

250

datasets available to search

ShareScore release 0.9.0

Reset

Dataset results

250 results for “Liver surgery;”

Learn how ShareScore rates datasets ↗
zenodo40/100

VISION Invited lecture - Bariatric surgery and non-alcoholic fatty liver disease

<p>Recording and presentation&nbsp;of the invited lecture that took place online on 16&nbsp;June 2021&nbsp;- <strong>Pantelis Antonakis, MD, PhD -&nbsp;Bariatric surgery and non-alcoholic fatty liver disease.</strong></p> <p>Bariatric surgery is a documented solution for morbid obesity. Additionally to excess weight loss, significant improvement in comorbidities is an established benefit after bariatric operations. In recent years, non-alcoholic fatty liver disease (NAFLD) has emerged as one of these comorbidities. Herein we will review the data supporting the positive effect of bariatric surgery in patients with NAFLD.</p>

opencc-by-4.0Jul 2021View details →
zenodo36/100

Raw Data for the article: How important is the role of iterative liver direct surgery in patients with hepatocellular carcinoma for a transplant center located in an area with a low rate of deceased donation?

<p><strong>Introduction:&nbsp;</strong>Hepatocellular carcinoma (HCC) accounts for nearly 90% of primary liver cancers, with estimates of over 1 million people affected by 2025. We aimed to explore the impacting role of an iterative surgical treatment approach in a cohort of HCC patients within the Milan criteria, associated with clinical risk factors for tumor recurrence (RHCC) after liver transplant (LT) and loco-regional therapies (LRT), as well as liver resection (LR) and/or microwave thermal ablation (MWTA).</p> <p><strong>Methods:&nbsp;</strong>We retrospectively analyzed our experience performed during an 8-year period between January 2013 and December 2021 in patients treated for HCC, focusing on describing the impact on preoperative end-stage liver disease severity, oncologic staging, tumor characteristics, and surgical treatments. The Cox model was used to evaluate variables that could predict relapse risks. Relapse risk curves were calculated according to the Kaplan-Meier method, and the log-rank test was used to compare them.</p> <p><strong>Results:&nbsp;</strong>There were 557 HCC patients treated with a first-line approach of LR and/or LRTs (<em>n</em>&nbsp;= 335) or LT (<em>n</em>&nbsp;= 222). The median age at initial transplantation was 59 versus 68 for those whose first surgical approach was LR and/or LRT. In univariate analysis with the Cox model, nodule size was the single predictor of recurrence of HCC in the posttreatment setting (HR: 1.61, 95% CI: 1.05-2.47,&nbsp;<em>p</em>&nbsp;= 0.030). For the LRT group, we have enlightened the following clinical characteristics as significantly associated with RHCC: hepatitis B virus infection (which has a protective role with HR: 0.34, 95% CI: 0.13-0.94,&nbsp;<em>p</em>&nbsp;= 0.038), number of HCC nodules (HR: 1.54, 95% CI: 1.22-1.94,&nbsp;<em>p</em>&nbsp;&lt; 0.001), size of the largest nodule (HR: 1.06, 95% CI: 1.01-1.12,&nbsp;<em>p</em>&nbsp;= 0.023), serum bilirubin (HR: 1.57, 95% CI: 1.03-2.40,&nbsp;<em>p</em>&nbsp;= 0.038), and international normalized ratio (HR: 16.40, 95% CI: 2.30-118.0,&nbsp;<em>p</em>&nbsp;= 0.006). Among the overall 111 patients with RHCC in the LRT group, 33 were iteratively treated with further curative treatment (12 were treated with LR, two with MWTA, three with a combined LR-MWTA treatment, and 16 underwent LT). Only one of 18 recurrent patients previously treated with LT underwent LR. For these RHCC patients, multivariable analysis showed the protective roles of LT for primary RHCC after IDLS (HR: 0.06, 95% CI: 0.01-0.36,&nbsp;<em>p</em>&nbsp;= 0.002), of the time relapsed between the first and second IDLS treatments (HR: 0.97, 95% CI: 0.94-0.99,&nbsp;<em>p</em>&nbsp;= 0.044), and the impact of previous minimally invasive treatment (HR: 0.28, 95% CI: 0.08-1.00,&nbsp;<em>p</em>&nbsp;= 0.051).</p> <p><strong>Conclusion:&nbsp;</strong>The coexistence of RHCC with underlying cirrhosis increases the complexity of assessing the net health benefit of ILDS before LT. Minimally invasive surgical therapies and time to HCC relapse should be considered an outcome in randomized clinical trials because they have a relevant impact on tumor-free survival.</p>

opencc-by-4.0Feb 2023View details →
ClinicalTrials.gov36/100

Chemoembolization Versus Radioembolization in Treating Patients With Liver Cancer That Cannot Be Treated With Radiofrequency Ablation Or Surgery

ClinicalTrials.gov study NCT00956930. IPD Sharing: NO. Countries: 1. Publications: 1.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov36/100

Chemoembolization and Bevacizumab in Treating Patients With Liver Cancer That Cannot Be Removed With Surgery

ClinicalTrials.gov study NCT00049322. IPD Sharing: Not stated. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

Tivozanib in Treating Patients With Liver Cancer That Is Metastatic or Cannot Be Removed by Surgery

ClinicalTrials.gov study NCT01835223. IPD Sharing: Not stated. Countries: 1. Publications: 4.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

GATT-Patch Versus TachoSil in Liver Surgery

ClinicalTrials.gov study NCT05385952. IPD Sharing: UNDECIDED. Countries: 3. Publications: 2.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

Sorafenib Tosylate and Yttrium Y 90 Glass Microspheres in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

ClinicalTrials.gov study NCT01900002. IPD Sharing: Not stated. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

Floxuridine and Dexamethasone as a Hepatic Arterial Infusion and Bevacizumab in Treating Patients With Primary Liver Cancer That Cannot be Removed by Surgery

ClinicalTrials.gov study NCT00410956. IPD Sharing: Not stated. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

Clinical Application of Image-Guided Liver Surgery

ClinicalTrials.gov study NCT00878215. IPD Sharing: NO. Countries: 1. Publications: 8.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov36/100

Biomarkers of Liver Pathology in Patients With Presumed Non-Alcoholic Steatohepatitis Following Bariatric Surgery

ClinicalTrials.gov study NCT03294850. IPD Sharing: NO. Countries: 1. Publications: 27.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov36/100

Belinostat in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery

ClinicalTrials.gov study NCT00321594. IPD Sharing: Not stated. Countries: 2. Publications: 2.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

A Study of Fibrocaps in Liver Surgery in the Netherlands

ClinicalTrials.gov study NCT01256190. IPD Sharing: Not stated. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

Effect of Human Plasma Protein Transfusion With and Without Crystalloids During Major Liver Resection Surgeries

ClinicalTrials.gov study NCT05033704. IPD Sharing: YES. Countries: 1. Publications: 12.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov36/100

Clinical Safety and Performance of GATT-Patch in Open Liver Surgery

ClinicalTrials.gov study NCT04819945. IPD Sharing: Not stated. Countries: 1. Publications: 2.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

Chemoembolization Using Doxorubicin in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery

ClinicalTrials.gov study NCT00293397. IPD Sharing: Not stated. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

Effect of Intermittent Pedicle Clamping on Hepatocellular Injury During Liver Surgery

ClinicalTrials.gov study NCT01099475. IPD Sharing: Not stated. Countries: 1. Publications: 2.

restrictedIPD-UNDECIDEDFeb 2026View details →
zenodo32/100

Supplementary tables- FGF21 and its underlying adipose tissue-liver axis inform cardiometabolic burden and improvement in obesity after metabolic surgery

Open the record for dataset details and reuse information.

opencc-by-4.0Nov 2024View details →
ClinicalTrials.gov32/100

The Effect of Remote Ischemic Preconditioning in Patients Undergoing Major Liver Surgery

ClinicalTrials.gov study NCT00796588. IPD Sharing: Not stated. Countries: 1. Publications: 2.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

ClinicalTrials.gov study NCT02072486. IPD Sharing: Not stated. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Application of 3D Printing in Laparoscopic Surgery of Liver Tumors

ClinicalTrials.gov study NCT03744624. IPD Sharing: UNDECIDED. Countries: 1. Publications: 3.

restrictedIPD-UNDECIDEDFeb 2026View details →

ScienceDex guides

Understand access before you commit

These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.

Compare curated datasets

Allen Brain Atlas

Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.

allen-brain-atlas
neuroscienceopenDocumentation, web resources, and API references are available online.
Last verified 2026-04-30Open record

Annotated Behaviour and Observability Dataset (ABODe)

ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.

abode-home-cage
behavioral-neuroscienceopenThe DataShare record exposes download links for annotations, documentation, license text, and the zipped per-snippet data directory.
Last verified 2026-04-30Open record

DANDI Archive for NWB datasets

DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.

dandi-nwb
electrophysiologyopenPublished Dandiset metadata and archive endpoints are available through the production DANDI API.
Last verified 2026-04-30Open record

International Brain Laboratory public data

The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.

ibl
behavioral-neuroscienceopenPublic sessions can be searched and loaded from the IBL public data server through ONE.
Last verified 2026-04-29Open record

OpenNeuro

OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.

openneuro
neuroscienceopenPublished datasets are available on demand over the internet.
Last verified 2026-04-29Open record